Mahsa Keshavarz-Fathi

Mahsa Keshavarz-Fathi

Auto-generated profile, based on publicly available information

Mahsa Keshavarz-Fathi

School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
MSMohammad Amin Sadeghi
Mohammad Amin Sadeghi
MKMahsa Keshavarz-Fathi
Mahsa Keshavarz-Fathi
VBVickie Baracos
Vickie Baracos
JAJann Arends
Jann Arends
MMMaryam Mahmoudi
Maryam Mahmoudi
NRNima Rezaei
Nima Rezaei

22 February 2021 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
RMRangarirai Makuku
Rangarirai Makuku
NKNeda Khalili
Neda Khalili
SRSepideh Razi
Sepideh Razi
MKMahsa Keshavarz-Fathi
Mahsa Keshavarz-Fathi
NRNima Rezaei
Nima Rezaei
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has yielded great success in recent years. Among immunotherapeutic agents, immune checkpoint inhibitors have been of particular interest and have gained approval by the FDA for treatment of cancers. Immune checkpoint blockade through targeting programmed cell death protein-1 (PD-1) has demonstrated promising antitumor effects in cancer immunotherapy of many different solid and hematologic malignancies. However, despite promising results, a favorable response is observed only in a fraction of patients, and there is still lack of a single therapy modality with curative ability. In this paper, we review the current and future perspectives of PD-1/L1 blockade in cancer immunotherapy, with a particular focus on predictive biomarkers of response to therapy. We also discuss the adverse events associated with PD-1/L1/2 inhibitors, ranging from severe life-threatening conditions such as autoimmune myocarditis to mild and moderate reactions such as skin rashes, and explore the potential strategies for improving the efficacy of immunotherapy with PD-1/L1 checkpoint inhibitors.

1 April 2019 in Cytokine
Verified
Journal Article
Closed access
SRSepideh Razi
Sepideh Razi
BNBehnoud Baradaran Noveiry
Behnoud Baradaran Noveiry
MKMahsa Keshavarz-Fathi
Mahsa Keshavarz-Fathi
NRNima Rezaei
Nima Rezaei

1 February 2018 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
SVSaeed Farajzadeh Valilou
Saeed Farajzadeh Valilou
MKMahsa Keshavarz-Fathi
Mahsa Keshavarz-Fathi
NSNicola Silvestris
Nicola Silvestris
AAAntonella Argentiero
Antonella Argentiero
NRNima Rezaei
Nima Rezaei

1 June 2020 in Cytokine
Verified
Journal Article
Closed access
Pouya Mahdavi SharifPouya Mahdavi Sharif
Pouya Mahdavi Sharif
PJParnian Jabbari
Parnian Jabbari
SRSepideh Razi
Sepideh Razi
MKMahsa Keshavarz-Fathi
Mahsa Keshavarz-Fathi
NRNima Rezaei
Nima Rezaei

7 August 2017 in Expert Review of Clinical Immunology
Verified
Journal Article
Closed access
HYHila Yousefi
Hila Yousefi
JYJianda Yuan
Jianda Yuan
MKMahsa Keshavarz-Fathi
Mahsa Keshavarz-Fathi
JMJoseph F Murphy
Joseph F Murphy
NRNima Rezaei
Nima Rezaei
Introduction: Cancer immunotherapy has evolved and is aimed at generating the efficacious therapeutic modality to enhance the specificity and power of the immune system to combat tumors. Areas covered: Current efforts in cancer immunotherapy fall into three main approaches. One approach is through the blockade of immune checkpoints, another approach is through adoptive cellular therapy, and the last approach is through vaccination. The goal of this review is to summarize the current understanding and status of cancer immunotherapy in these three categories. Expert commentary: We foresee the development of therapeutic protocols combining these approaches with each other or conventional therapies to achieve the most appropriate guideline for management of cancer.